vs
KFORCE INC（KFRC）与Royalty Pharma plc（RPRX）财务数据对比。点击上方公司名可切换其他公司
Royalty Pharma plc的季度营收约是KFORCE INC的1.9倍（$622.0M vs $330.4M），Royalty Pharma plc净利率更高（34.4% vs 2.4%，领先32.0%），Royalty Pharma plc同比增速更快（4.8% vs 0.1%），过去两年Royalty Pharma plc的营收复合增速更高（4.6% vs -3.7%）
Kforce Inc.是一家总部位于美国的专业人力资源服务与解决方案供应商，业务覆盖技术、财务会计、医疗保健三大核心领域，为全美各类中大型企业提供专业人才派遣、劳动力管理优化等定制服务。
本公司是总部位于美国马萨诸塞州剑桥市的临床阶段生物制药企业，专注于研发可调节转化生长因子β（TGF-β）超家族蛋白的药物，该类蛋白在红细胞、肌肉、骨骼、血管等细胞与组织的生长修复过程中发挥核心作用。
KFRC vs RPRX — 直观对比
营收规模更大
RPRX
是对方的1.9倍
$330.4M
营收增速更快
RPRX
高出4.7%
0.1%
净利率更高
RPRX
高出32.0%
2.4%
两年增速更快
RPRX
近两年复合增速
-3.7%
损益表 — Q1 FY2026 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $330.4M | $622.0M |
| 净利润 | $7.9M | $214.2M |
| 毛利率 | 27.3% | — |
| 营业利润率 | 3.6% | 62.4% |
| 净利率 | 2.4% | 34.4% |
| 营收同比 | 0.1% | 4.8% |
| 净利润同比 | -2.7% | 2.9% |
| 每股收益（稀释后） | $0.46 | $0.49 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收KFRCRPRX
| Q1 26 | $330.4M | — | ||
| Q4 25 | $332.0M | $622.0M | ||
| Q3 25 | $332.6M | $609.3M | ||
| Q2 25 | $334.3M | $578.7M | ||
| Q1 25 | $330.0M | $568.2M | ||
| Q4 24 | $343.8M | $593.6M | ||
| Q3 24 | $353.3M | $564.7M | ||
| Q2 24 | $356.3M | $537.3M |
净利润KFRCRPRX
| Q1 26 | $7.9M | — | ||
| Q4 25 | $5.2M | $214.2M | ||
| Q3 25 | $11.1M | $288.2M | ||
| Q2 25 | $10.4M | $30.2M | ||
| Q1 25 | $8.1M | $238.3M | ||
| Q4 24 | $11.1M | $208.2M | ||
| Q3 24 | $14.2M | $544.0M | ||
| Q2 24 | $14.2M | $102.0M |
毛利率KFRCRPRX
| Q1 26 | 27.3% | — | ||
| Q4 25 | 27.2% | — | ||
| Q3 25 | 27.7% | — | ||
| Q2 25 | 27.1% | — | ||
| Q1 25 | 26.7% | — | ||
| Q4 24 | 27.0% | — | ||
| Q3 24 | 27.9% | — | ||
| Q2 24 | 27.8% | — |
营业利润率KFRCRPRX
| Q1 26 | 3.6% | — | ||
| Q4 25 | 2.6% | 62.4% | ||
| Q3 25 | 4.5% | 70.1% | ||
| Q2 25 | 4.5% | 36.3% | ||
| Q1 25 | 3.5% | 94.0% | ||
| Q4 24 | 4.5% | 60.9% | ||
| Q3 24 | 5.3% | — | ||
| Q2 24 | 5.5% | 50.2% |
净利率KFRCRPRX
| Q1 26 | 2.4% | — | ||
| Q4 25 | 1.6% | 34.4% | ||
| Q3 25 | 3.3% | 47.3% | ||
| Q2 25 | 3.1% | 5.2% | ||
| Q1 25 | 2.5% | 41.9% | ||
| Q4 24 | 3.2% | 35.1% | ||
| Q3 24 | 4.0% | 96.3% | ||
| Q2 24 | 4.0% | 19.0% |
每股收益（稀释后）KFRCRPRX
| Q1 26 | $0.46 | — | ||
| Q4 25 | $0.29 | $0.49 | ||
| Q3 25 | $0.63 | $0.67 | ||
| Q2 25 | $0.59 | $0.07 | ||
| Q1 25 | $0.45 | $0.55 | ||
| Q4 24 | $0.60 | $0.46 | ||
| Q3 24 | $0.75 | $1.21 | ||
| Q2 24 | $0.75 | $0.23 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $1.3M | $618.7M |
| 总债务越低越好 | — | $9.0B |
| 股东权益账面价值 | $117.4M | $9.7B |
| 总资产 | $384.8M | $19.6B |
| 负债/权益比越低杠杆越低 | — | 0.92× |
8季度趋势，按日历期对齐
现金及短期投资KFRCRPRX
| Q1 26 | $1.3M | — | ||
| Q4 25 | $2.1M | $618.7M | ||
| Q3 25 | $1.3M | $938.9M | ||
| Q2 25 | $2.5M | $631.9M | ||
| Q1 25 | $444.0K | $1.1B | ||
| Q4 24 | $349.0K | $929.0M | ||
| Q3 24 | $127.0K | $950.1M | ||
| Q2 24 | $110.0K | $1.8B |
总债务KFRCRPRX
| Q1 26 | — | — | ||
| Q4 25 | — | $9.0B | ||
| Q3 25 | — | $8.9B | ||
| Q2 25 | — | $8.0B | ||
| Q1 25 | — | $7.6B | ||
| Q4 24 | — | $7.6B | ||
| Q3 24 | — | $7.6B | ||
| Q2 24 | — | $7.6B |
股东权益KFRCRPRX
| Q1 26 | $117.4M | — | ||
| Q4 25 | $124.6M | $9.7B | ||
| Q3 25 | $132.1M | $9.6B | ||
| Q2 25 | $134.4M | $9.5B | ||
| Q1 25 | $138.0M | $9.8B | ||
| Q4 24 | $154.6M | $10.3B | ||
| Q3 24 | $167.4M | $10.3B | ||
| Q2 24 | $166.6M | $9.8B |
总资产KFRCRPRX
| Q1 26 | $384.8M | — | ||
| Q4 25 | $365.6M | $19.6B | ||
| Q3 25 | $374.2M | $19.3B | ||
| Q2 25 | $373.6M | $18.3B | ||
| Q1 25 | $368.2M | $17.6B | ||
| Q4 24 | $357.8M | $18.2B | ||
| Q3 24 | $369.9M | $18.0B | ||
| Q2 24 | $362.7M | $17.7B |
负债/权益比KFRCRPRX
| Q1 26 | — | — | ||
| Q4 25 | — | 0.92× | ||
| Q3 25 | — | 0.93× | ||
| Q2 25 | — | 0.84× | ||
| Q1 25 | — | 0.78× | ||
| Q4 24 | — | 0.74× | ||
| Q3 24 | — | 0.74× | ||
| Q2 24 | — | 0.78× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | — | $827.1M |
| 自由现金流经营现金流 - 资本支出 | $-7.4M | — |
| 自由现金流率自由现金流/营收 | -2.2% | — |
| 资本支出强度资本支出/营收 | 1.0% | — |
| 现金转化率经营现金流/净利润 | — | 3.86× |
| 过去12个月自由现金流最近4个季度 | $43.3M | — |
8季度趋势，按日历期对齐
经营现金流KFRCRPRX
| Q1 26 | — | — | ||
| Q4 25 | $19.7M | $827.1M | ||
| Q3 25 | $23.3M | $702.6M | ||
| Q2 25 | $18.4M | $364.0M | ||
| Q1 25 | $249.0K | $596.1M | ||
| Q4 24 | $21.8M | $742.5M | ||
| Q3 24 | $31.0M | $703.6M | ||
| Q2 24 | $20.9M | $658.2M |
自由现金流KFRCRPRX
| Q1 26 | $-7.4M | — | ||
| Q4 25 | $16.7M | — | ||
| Q3 25 | $19.8M | — | ||
| Q2 25 | $14.2M | — | ||
| Q1 25 | $-3.9M | — | ||
| Q4 24 | $20.9M | — | ||
| Q3 24 | $27.5M | — | ||
| Q2 24 | $17.8M | — |
自由现金流率KFRCRPRX
| Q1 26 | -2.2% | — | ||
| Q4 25 | 5.0% | — | ||
| Q3 25 | 6.0% | — | ||
| Q2 25 | 4.3% | — | ||
| Q1 25 | -1.2% | — | ||
| Q4 24 | 6.1% | — | ||
| Q3 24 | 7.8% | — | ||
| Q2 24 | 5.0% | — |
资本支出强度KFRCRPRX
| Q1 26 | 1.0% | — | ||
| Q4 25 | 0.9% | — | ||
| Q3 25 | 1.1% | — | ||
| Q2 25 | 1.2% | — | ||
| Q1 25 | 1.3% | — | ||
| Q4 24 | 0.3% | — | ||
| Q3 24 | 1.0% | — | ||
| Q2 24 | 0.9% | — |
现金转化率KFRCRPRX
| Q1 26 | — | — | ||
| Q4 25 | 3.82× | 3.86× | ||
| Q3 25 | 2.11× | 2.44× | ||
| Q2 25 | 1.76× | 12.06× | ||
| Q1 25 | 0.03× | 2.50× | ||
| Q4 24 | 1.97× | 3.57× | ||
| Q3 24 | 2.18× | 1.29× | ||
| Q2 24 | 1.48× | 6.45× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
KFRC
暂无分部数据
RPRX
| Financial Royalty Assets | $592.4M | 95% |
| Royalty Income Other | $29.6M | 5% |
